The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors

Author： Belani Chandra P.  

Publisher： Informa Healthcare

ISSN： 0735-7907

Source： Cancer Investigation, Vol.28, Iss.4, 2010-04, pp. : 413-423

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

ABSTRACTReversible epidermal growth factor receptor tyrosine kinase inhibitors are often used for the treatment of non-small cell lung cancer following failure of cytotoxic chemotherapy. While these agents are active in a subset of patients, most develop resistance and progress within the course of 1 year. In nearly half of the cases, acquired resistance is caused by a secondary epidermal growth factor receptor T790M mutation. Irreversible epidermal growth factor receptor tyrosine kinase inhibitors are an emerging class of agents that may have the potential to overcome and prevent the emergence of such mutation-related resistance.

Related content

EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992

By Spicer James  

Targeted Oncology, Vol. 5, Iss. 4, 2010-12 ,pp. : 245-255 (11)

Springer Publishing Company

Access to resources Recommend Favorite

Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer

By  

Oncology Reports, Vol. 33, Iss. 1, 2015-01 ,pp. : 391-396 (6)

Spandidos Publications

Access to resources Recommend Favorite

EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer

By Kao Hsiang-Fong   Lin Chia-Chi   Yang James Chih-Hsin  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 991-1003 (13)

Future Medicine

Access to resources Recommend Favorite

EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?

By Califano Raffaele  

Targeted Oncology, Vol. 3, Iss. 3, 2008-07 ,pp. : 173-186 (14)

Springer Publishing Company

Access to resources Recommend Favorite

Predictors of outcome for EGFR-mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors

By Pilotto Sara   Bria Emilio  

Lung Cancer Management, Vol. 2, Iss. 2, 2013-04 ,pp. : 89-92 (4)

Future Medicine

Access to resources Recommend Favorite